Automatic bone marrow segmentation for precise [177Lu]Lu‐PSMA‐617 dosimetry
Sign Up to like & getrecommendations! Published in 2025 at "Medical Physics"
DOI: 10.1002/mp.17684
Abstract: Bone marrow (BM) is the dominant dose‐limiting organ in [177Lu]Lu‐PSMA‐617 therapy for patients with metastasized castration resistant prostate cancer, where BM dosimetry is challenging due to segmentation. read more here.
Keywords: bone marrow; 177lu psma; psma 617;
Transforming [177Lu]Lu‐PSMA‐617 treatment planning: Machine learning‐based radiodosiomics and swin UNETR using pretherapy PSMA positron emission tomography/computed tomography (PET/CT)
Sign Up to like & getrecommendations! Published in 2025 at "Medical Physics"
DOI: 10.1002/mp.70030
Abstract: Personalized pretreatment dosimetry planning is crucial for optimizing [177Lu]Lu–prostate‐specific membrane antigen‐617 (Lu‐PSMA) radioligand therapy (RLT) in patients with metastatic castration‐resistant prostate cancer (mCRPC). read more here.
Keywords: psma 617; 617 treatment; transforming 177lu; psma ... See more keywords
The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-017-3681-9
Abstract: Background[177Lu]Lu-PSMA-617 is a well-tolerated therapy for the treatment of metastatic prostate cancer. However, because of the mainly renal excretion of the tracer, the kidneys are one of the most limiting organs. The purpose of this… read more here.
Keywords: psma 617; 177lu psma; metastatic prostate; prostate cancer ... See more keywords
177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-017-3751-z
Abstract: PurposeRadioligand therapies targeting prostate-specific membrane antigen (PSMA) have been established for the treatment of metastasized castration-resistant prostate cancer (mCRPC) in the last decade and show promising response rates and a favourable toxicity profile. The aim… read more here.
Keywords: prostate; psma 617; 177lu psma; prostate cancer ... See more keywords
225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-019-04612-0
Abstract: Up to 30% of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) never respond or develop resistance to 177Lu-labeled PSMA-targeted radioligand monotherapy. Single-agent PSMA-targeted radioligand therapy (PRLT) with the alpha-emitter 225Ac showed… read more here.
Keywords: psma 617; 177lu psma; 225ac psma; tandem therapy ... See more keywords
Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-020-04715-z
Abstract: Glioblastoma multiforme (GBM) is the most malignant primary brain tumor with limited treatment options in case of recurrence. Prostate-specific membrane antigen (PSMA) expression was demonstrated in microvascular endothelium of GBM and in vivo confirmed by… read more here.
Keywords: psma 617; treatment; glioblastoma multiforme; psma ... See more keywords
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-020-05057-6
Abstract: Various radiolabeled prostate-specific membrane antigen (PSMA)–targeting tracers are clinically applied for prostate cancer (PCa) imaging and targeted radionuclide therapy. The PSMA binding affinities, biodistribution, and DNA-damaging capacities of these radiotracers have not yet been compared… read more here.
Keywords: psma 617; 177lu psma; prostate cancer; evaluation ... See more keywords
Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-022-05778-w
Abstract: Actinium-225-labeled prostate-specific membrane antigen ([225Ac]Ac-PSMA-617) is safe and effective in the treatment of metastatic castration-resistant prostate cancer (mCRPC). No study has specifically assessed its safety in patients with extensive skeletal metastases of mCRPC. We aimed… read more here.
Keywords: toxicity; hematologic toxicity; treatment; skeletal metastases ... See more keywords
Efficacy and safety of rechallenge [177Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)
Sign Up to like & getrecommendations! Published in 2024 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-024-06825-4
Abstract: Rechallenge of [177Lu]Lu-PSMA-617 radioligand therapy (RLT) was proposed for patients who initially responded to PSMA-RLT experiencing partial remission, but relapsed into progression after a certain period of remission. However, only limited data is available regarding… read more here.
Keywords: 617 rlt; rlt; psma 617; rechallenge ... See more keywords
Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer
Sign Up to like & getrecommendations! Published in 2025 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-025-07330-y
Abstract: Metastatic castration-resistant prostate cancer (mCRPC) frequently leads to bone and soft tissue metastases, leading to poor prognosis. The beta-emitting radioligand [177Lu]Lu-PSMA-617 targets the prostate-specific membrane antigen (PSMA) and may be less efficient against micrometastatic disease.… read more here.
Keywords: prostate cancer; psma 617; 212pb ab001; psma ... See more keywords
A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Imaging and Biology"
DOI: 10.1007/s11307-017-1121-7
Abstract: PurposeProstate-specific membrane antigen (PSMA) comprises a recognized target for molecular imaging of prostate cancer. As such, radiolabeled PSMA inhibitors are of great value for diagnosis and staging of this disease. Herein, we disclose the preclinical… read more here.
Keywords: imaging prostate; psma 617; pet imaging; prostate cancer ... See more keywords